
Talis Biomedical Investor Relations Material
Latest events

Q2 2023
Talis Biomedical

Q2 2024
18 Aug, 2024

Q1 2024
8 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Talis Biomedical Corp
Access all reports
Talis Biomedical Corp is a molecular diagnostic company focused on health and patient outcomes through the development and delivery of accurate infectious disease testing at the point of care. The company's efforts are concentrated on diagnosing infectious diseases rapidly, accurately, and directly at the point-of-care. Their product development includes the Talis One system, designed to overcome the limitations of existing point-of-care diagnostic testing technologies, with applications in respiratory infections, women's health infections, sexually transmitted infections, and more. The company is headquartered in Redwood City, California and its shares are listed on the Nasdaq.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
TLIS
Country
🇺🇸 United States